Roivant Sciences (ROIV) EBIT Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) EBIT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Insmed | 28.20 Bn | 27.04 Bn | 358.27 Mn | 29,091.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.23 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.19 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | -177,280.00 |
| Jun 30, 2024 | -127.00 |
| Dec 31, 2023 | 2.44 Mn |
| Sep 30, 2023 | -362,303.00 |
| Jun 30, 2023 | 525,817.00 |
| Dec 31, 2022 | -42,081.00 |
| Sep 30, 2022 | 265,311.00 |
| Jun 30, 2022 | -454,049.00 |
| Dec 31, 2021 | 215,045.00 |
| Sep 30, 2021 | 693,895.00 |
| Jun 30, 2021 | 526,629.00 |